Global and regional trends in Clostridioides difficile infection: an analysis from 1990 to 2021.|https://dx.doi.org/10.1016/j.jgar.2025.04.001
Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients.|https://dx.doi.org/10.1093/crocol/otaf021
Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.|https://dx.doi.org/10.1016/j.ymgmr.2025.101215
Rifaximin-Î± use is associated with improved muscle mass in patients with cirrhosis.|https://dx.doi.org/10.4254/wjh.v17.i4.104056
Impact of a Collaboration-Focused Intervention to Prevent Healthcare-Associated Infections Before and During the Coronavirus Disease 2019 Pandemic.|https://dx.doi.org/10.1093/cid/ciaf122
Association of Clostridium difficile infection with clinical outcomes of patients with inflammatory bowel disease: A meta-analysis.|https://dx.doi.org/10.4240/wjgs.v17.i4.100555
